Harvard Bioscience (HBIO) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts HBIO Hot Sheet
Price: $8.76 +1.86%
EPS Growth %: -800.0%
Financial Fact:
Other income (expense), net: -67K
Today's EPS Names:
FUSE, INM, TRI, More
EPS Growth %: -800.0%
Financial Fact:
Other income (expense), net: -67K
Today's EPS Names:
FUSE, INM, TRI, More
Join SI Premium – FREE
Harvard Bioscience (NASDAQ: HBIO) reported Q4 EPS of $0.04, $0.01 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $28.4 million versus the consensus estimate of $30.4 million.
For earnings history and earnings-related data on Harvard Bioscience (HBIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Super Micro Computer (SMCI) Tops Q1 EPS by 58c, Offers Guidance
- IFF (IFF) Tops Q3 EPS by 2c; raises guidance
- Advanced Micro Devices, Inc. (AMD) Tops Q3 EPS by 15c, Beats on Revenue; Offers Q4 Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
